Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, . . . Chongqing Tan. (2022). Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers Media S.A..
Chicago Style (17th ed.) CitationYe Peng, et al. Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationYe Peng, et al. Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.